Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Friday, March 29, 2024 · 699,741,787 Articles · 3+ Million Readers

Visiongain Launches New Report on the Generic Drugs Market 2018-2028

LONDON, May 21, 2018 (GLOBE NEWSWIRE) -- Visiongain has launched a new pharma report Generic Drugs Market Forecast 2018-2028: Growth in Leading Regional and National Markets – North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico

The generic drugs market has historically increased at near double-digit growth rates over the last three decades, compared to single-digit growth for the pharmaceutical market as a whole. The industry has benefited from increasing generic penetration in most major markets notable exceptions being Japan, France, Italy and Spain, where generic penetration is increasing slowly. This trend is likely to continue as falling R&D productivity begins to limit revenues for innovator companies while cost pressures encourage the growth of generic sales by volume.

The lead analyst of the report commented, The socio-economic landscape of many national and regional markets globally has been changing immensely over the last decade. This factor, coupled with the changing in the demographics of these regions will help to shape the future direction of generic drugs over the next 10 years. Population growth and ageing are expected to increase the burden of disease, especially chronic diseases such as diabetes and hypertension. This will be a major driver of the demand for generic medicines during the forecast period.

Leading companies featured in the report include Teva, Novartis (Sandoz), Allergan, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy’s Laboratories, Apotex

To request your free report overview please contact Sara Peerun on sara.peerun@vsiongain.com or call +44 207 549 9987

All the companies listed in the report include:

Abbott
AbbVie
Able Laboratories
Aché
Actavis
Alcon (Novartis)
Allergan (Actavis)
Amgen
Anda Inc
Apotex
APP Pharmaceuticals
Arrow Group (Actavis)
Ascent Pharmahealth (Actavis)
ASKA Pharmaceuticals
Aspen
AstraZeneca
Aurobindo
Auspex Pharmaceuticals
Bedford Laboratories
Bergamo (Amgen)
Biocon
Bioniche Pharma (Mylan)
BMP Sunstone (Sanofi)
Caraco
Celltrion
CFR Pharmaceuticals (Abbott)
Cipla
Claris
Dabur Pharma (Fresenius Kabi)
Daiichi Sankyo
Dalim BioTech
Dr Reddy’s Laboratory
Ebewe Pharma (Novartis)
Eden Biopharm Group
Egis
Elder Pharmaceuticals (Torrent Pharmaceuticals)
Eli Lilly
Elyson Pharmaceuticals
EMS Sigma Pharma
Eon Labs
Eurofarma Laboratories
Farmacias Similares
Fenwal (Fresenius Kabi)

To request your free report overview please contact Sara Peerun on sara.peerun@vsiongain.com or call +44 207 549 9987

Forest Laboratories (Actavis)
Foshan Chanbende Development
Fougera Pharmaceuticals (Novartis)
Fresenius Kabi
Fresenius SE & Co
Fuji Pharma
Gavis Pharmaceuticals
Gedeon Richter
Genfar S.A (Sanofi)
Genzyme (Sanofi)
Gilead Sciences
GlaxoSmithKline (GSK)
Greenstone (Pfizer)
Grupo Sanborns
Grupo Uriach
Hexal
Hospira (Pfizer)
IDEV Technologies (Abbott)
Ilsung Pharmaceuticals
Imperial Credit Private Limited
InnoPharma Inc
Itero Biopharmaceuticals
Janssen
Javelin Pharmaceuticals (Hospira)
Johnson & Johnson
Kmart
KMS Pharmaceutical
Kowa Pharmaceuticals
Krka
Labesfal Genéricos (Fresenius Kabi)
Laboratorio Sanderson (Fresenius Kabi)
Laboratorios Best
Laboratorios Kendrick (Sanofi)
Lek (Novartis)
Lundbeck
Lupin
Matrix Laboratories
Mayne Pharma (Hospira)
Meda AB
Medley (Sanofi)
Merck KGaA
MN Pharma (Amgen)
Momenta Pharmaceuticals
Mylan
Natco Pharma
Nexus Pharmaceuticals
Nichi-Iko
Nippon Chemiphar
Novartis (Sandoz)
Novo Nordisk
OptiMedica (Abbott)
Orchid Chemicals & Pharmaceuticals
Oriel Therapeutics (Novartis)
Parenteral Drugs India Ltd
Perrigo
Pfizer
Piramal (Abbott Laboratories)
Pliva (Teva)
PT Soho Global Health
Ranbaxy (Sun Pharmaceuticals)
Ratiopharm
Rimsa
Roche
Sabex (Novartis)
Sanofi
Sawai Pharmaceuticals
Schein Pharmaceutical (Actavis)
Servier
Shelys (Aspen)
Sigma Pharmaceuticals (Aspen)
Solvay Pharmaceuticals (Abbott)
Specifar Pharmaceuticals (Actavis)
St. Jude Medical
STADA Arzneimittel
Strides Arcolab
Sun Pharma
Synthon
Taiyo Pharmaceuticals
Takeda
Teuto Brasileiro (Pfizer)
Teva
The Laboratory of Analytical Services International Ltd
Towa
UDL Laboratories
Uteron Pharma (Actavis)
Valeant Pharmaceuticals
Wal-Mart
Warner Chilcott (Actavis)
Watson
Wockhardt
Wyeth (Pfizer)
Zentiva (Sanofi)
Zhejiang Chiral Medicine Chemicals Co. Ltd
Zhejiang Hisun Pharmaceutical
Zydus Cadila

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 208 781 6953

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent.

To request your free report overview please contact Sara Peerun on sara.peerun@vsiongain.com or call +44 207 549 9987

Primary Logo

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release